All time hard disease

Asking for Preferences

Reading File

Finding Sources

Reading File

Here is a breakdown of the hardest diseases to treat or cure, drawn from authoritative medical textbooks:

The Hardest Diseases to Treat or Cure

1. 🧠 Prion Diseases (CJD, Fatal Familial Insomnia, Kuru)

Verdict: Uniformly fatal — no effective treatment exists

Prion diseases are caused by misfolded proteins (PrP^Sc) that propagate by converting normal brain proteins. They are unique in being transmissible yet not caused by a virus or bacterium.

"Currently, there is no known cure for human prion diseases; all cases are uniformly fatal." — Bradley and Daroff's Neurology in Clinical Practice

Drugs tested in randomized controlled trials — including quinacrine, flupirtine, and doxycycline — failed to prolong survival. Experimental approaches (e.g., anti-PrP^C antibody PRN100) are being explored but remain unproven. The disease progresses relentlessly from onset to death, typically within months to a year.

2. 🧬 Glioblastoma (Grade IV Brain Cancer)

Verdict: Near-universally fatal; median survival ~15–18 months

Glioblastoma is the most common malignant primary brain tumor, accounting for >12,000 new U.S. cases per year.

"Despite optimal therapy, glioblastomas invariably recur." — Harrison's Principles of Internal Medicine, 22E

The standard regimen (maximal resection + radiation + temozolomide chemotherapy) only extends median survival to 15–18 months, and 5-year survival is ~10%. Tumors with the MGMT enzyme are particularly resistant to chemotherapy. Even bevacizumab (anti-VEGF), while improving progression-free survival, does not improve overall survival in recurrent disease.

3. 🩸 Multiple Myeloma (Plasma Cell Cancer)

Verdict: Incurable; manageable but relapsing

"MM is considered an incurable disease, with most patients..." — Tietz Textbook of Laboratory Medicine, 7th Edition

Despite major advances in treatment (proteasome inhibitors, IMiDs, CAR-T therapy), multiple myeloma remains incurable in the vast majority of patients. Treatment achieves remission, but relapse is nearly universal.

4. 💪 Duchenne Muscular Dystrophy (DMD)

Verdict: Incurable; life-limiting progressive muscle degeneration

DMD is caused by mutations in the dystrophin gene, leading to progressive loss of muscle function and early death (typically in the 20s–30s).

"The life-threatening and debilitating nature of DMD, and the lack of available therapy has opened new hope for what has been considered an incurable and untreatable disorder." — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Newer gene-targeted therapies (exon skipping) are emerging but remain limited in their scope and benefit.

5. 🦾 Amyotrophic Lateral Sclerosis (ALS)

Verdict: Fatal; median survival 2–5 years from diagnosis

ALS destroys motor neurons progressively, leading to paralysis, respiratory failure, and death. Prion-like spreading of misfolded SOD1 and TDP-43 proteins drives the disease.

"Prion-like spreading in ALS." — Bradley and Daroff's Neurology in Clinical Practice

Only riluzole and edaravone are approved treatments — neither stops the disease, they only modestly slow progression.

6. 🫀 Cardiac Amyloidosis (Historically)

Verdict: Historically incurable; now increasingly treatable

Once considered both rare and untreatable, cardiac amyloidosis has seen dramatic therapeutic advances (tafamidis, patisiran), making it a rare success story among previously incurable diseases.

"A disease that formerly was conceived as uncommon and untreatable is now increasingly recognized..." — Braunwald's Heart Disease

7. 🦠 Rabies

Verdict: Essentially 100% fatal once symptomatic

Once clinical symptoms appear, rabies is almost universally fatal. Pre- and post-exposure prophylaxis (vaccine) is effective, but there is no established treatment after neurological symptoms begin. The "Milwaukee Protocol" has had rare anecdotal successes but is not reproducibly effective.

Why Are These Diseases So Hard to Treat?

Reason	Examples
No druggable target identified	Prion diseases
Brain/CNS drug penetration barriers	Glioblastoma, ALS
Tumor microenvironment suppresses immunity	Glioblastoma
Genetic complexity / multiple mutations	Multiple myeloma
Disease too advanced at diagnosis	Many cancers
Pathogen hides from immune system	HIV (chronic), Rabies
Protein misfolding cascade irreversible	Prions, ALS

The diseases above represent the frontier of medicine — areas where current science, despite enormous effort, has not yet found a cure.

Stomach ulcer differential diagnosis treatment and investigation

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Here is a comprehensive clinical overview of Peptic Ulcer Disease (Gastric/Stomach Ulcer) — covering differential diagnosis, investigations, and treatment — drawn from major gastroenterology and clinical medicine textbooks.

Peptic Ulcer Disease (Stomach Ulcer)

Definition

A peptic ulcer occurs when inflammation causes loss of the mucosa and muscularis mucosa, often extending into the submucosa and muscularis propria. Gastric ulcers are located in the stomach; duodenal ulcers in the first part of the duodenum. Together, they constitute 30–50% of all upper GI bleeding admissions.

Aetiology & Risk Factors

Cause	Detail
H. pylori infection	Most common cause — ~90% of duodenal ulcers worldwide; 30–40% in the US
NSAIDs / Aspirin	Second most common; inhibit prostaglandins → disrupts mucosal protection
Smoking	Delays healing, increases recurrence
Zollinger–Ellison syndrome	Gastrin-secreting tumour → massive acid hypersecretion
Corticosteroids	Especially combined with NSAIDs
Crack cocaine / methamphetamine	Illicit drug use
Immunocompromised state	CMV, HSV, fungal infections can cause atypical ulcers
Systemic mastocytosis	Rare
Blood group O	Genetically linked to higher duodenal ulcer risk

"Cumulative lifetime prevalence of PUD is 8–14%" — Textbook of Family Medicine 9e

Clinical Presentation

Epigastric pain — burning or gnawing; often worsens after meals (gastric ulcer) or relieved by food (duodenal ulcer)
Nausea, bloating, early satiety
Alarm symptoms (red flags): rectal bleeding/melena, unintentional weight loss, anorexia, persistent vomiting, dysphagia, anaemia, palpable mass
Complications: upper GI haemorrhage (up to 15%), perforation (~7%), gastric outlet obstruction, penetration into adjacent organs

Differential Diagnosis

Common

Condition	Distinguishing Features
Gastro-oesophageal reflux disease (GERD)	Heartburn, regurgitation; worse lying down/after meals
Functional (non-ulcer) dyspepsia	No structural lesion on endoscopy; diagnosis of exclusion
Peptic ulcer disease	Epigastric pain; H. pylori or NSAID history

Less Common

Condition	Distinguishing Features
GI malignancy (gastric cancer)	Alarm symptoms, older age, progressive weight loss
Pancreatitis	Epigastric pain radiating to back, elevated lipase/amylase
Biliary colic	Right upper quadrant, post-fatty meal colicky pain
Gastroparesis	Early satiety, nausea, bloating — often in diabetics
Zollinger–Ellison syndrome	Multiple refractory ulcers, severe GERD, diarrhoea
Intestinal ischaemia	Postprandial pain, weight loss, vascular risk factors
Celiac sprue	Diarrhoea, malabsorption, bloating
Lactose intolerance	Bloating, diarrhoea after dairy
Viral/bacterial gastroenteritis	Acute onset, fever, diarrhoea

Investigations

Step 1 — Who Needs Endoscopy?

Age >45 years with new-onset dyspepsia → upper GI endoscopy (AGA guideline)
Any age with alarm symptoms → urgent endoscopy
Younger patients without alarm symptoms → "test and treat" H. pylori strategy first

Non-invasive H. pylori Testing

Test	Details
Stool antigen test	Preferred initial non-invasive test
Urea breath test (¹³C)	Most accurate non-invasive test; gold standard to confirm eradication
Serum IgG serology	Sensitivity 92%, specificity 83%; may remain positive months–years after eradication (false positives)

Urea Breath Test: H. pylori urease splits labelled urea → exhaled ¹³CO₂ detected

Invasive — Upper GI Endoscopy

Gold standard for diagnosis; allows direct visualisation, biopsy, and therapeutic intervention
Document: ulcer location, size, number, edge characteristics, presence of mass or nodules
Biopsy of gastric ulcers is mandatory (to exclude malignancy) — biopsies also detect H. pylori on gastric mucosa
Forrest classification of stigmata of recent haemorrhage (used in Europe/Asia):
- High risk: active spurting/oozing, non-bleeding visible vessel
- Intermediate: adherent clot
- Low risk: flat pigmented spot, clean base

Endoscopic stigmata of recent hemorrhage — peptic ulcers

(a) Clean base — near-zero rebleeding risk; (b) Adherent clot — intermediate risk; (c) Adherent clot with vessel; (d) Non-bleeding visible vessel — 40–50% rebleed risk; (e) Active bleeding — ~60% rebleed risk — Yamada's Textbook of Gastroenterology

Other Investigations

Test	Purpose
FBC	Anaemia from chronic/acute blood loss
Urea & Creatinine	Urea often elevated in upper GI bleed (blood digestion)
Coagulation screen	If bleeding suspected
Serum gastrin	If Zollinger–Ellison suspected (multiple/refractory ulcers)
Erect CXR / AXR	Subdiaphragmatic free air if perforation suspected
Rockall Score	Risk stratification for rebleeding and mortality in GI haemorrhage

Treatment

1. H. pylori Eradication (First-line for H. pylori-positive PUD)

14-day Triple Therapy (preferred when clarithromycin resistance is low):

PPI + Clarithromycin + Amoxicillin (or Metronidazole if penicillin-allergic)

Eradication rate: 70–85%

Bismuth Quadruple Therapy (first-line OR salvage if triple therapy fails):

PPI + Bismuth subsalicylate + Metronidazole + Tetracycline

Eradication rate: ≥90%

Successful eradication eliminates ulcer recurrence — recurrence drops from 60–100%/year (with acid suppression alone) to <15% after eradication.

Confirm eradication with urea breath test or stool antigen ≥4 weeks after completing therapy.

2. Acid Suppression

Drug Class	Examples	Mechanism
Proton Pump Inhibitors (PPIs)	Omeprazole, Pantoprazole, Lansoprazole	Inhibit H⁺/K⁺-ATPase proton pump; most potent acid suppressors
H2 Receptor Antagonists	Famotidine, Nizatidine, Cimetidine	Block histamine H2 receptors → reduce acid secretion
Antacids	Aluminium hydroxide, Calcium carbonate, Magnesium hydroxide	Neutralise gastric acid; short-term symptom relief

After haemostasis in bleeding ulcers: IV PPI for 72 hours, then daily PPI for ≥8 weeks

3. Mucosal Protective Agents

Agent	Role
Sucralfate	Forms protective coat over ulcer base
Bismuth subsalicylate	Mucosal protection + antibacterial (part of quadruple therapy)

4. NSAID-related Ulcers

Stop NSAID if possible
Prescribe a PPI for ulcer healing
If NSAID must continue (e.g. for cardiovascular reasons): use a COX-2 inhibitor + PPI
High-risk patients (elderly, prior PUD, on anticoagulants/corticosteroids): prophylactic PPI or H2RA

5. Test-and-Treat Strategy (Primary Care)

For patients <45 years with dyspepsia, no alarm symptoms:

Test for H. pylori (stool antigen preferred)
Treat if positive; proceed to endoscopy if symptoms persist despite treatment

6. Surgical / Endoscopic Management (Complications)

Bleeding ulcer (endoscopic haemostasis):

Injection of adrenaline (epinephrine) + thermal coagulation or mechanical clips
Avoid epinephrine alone — combination therapy reduces rebleeding
Surgery or interventional radiology if endoscopic haemostasis fails

Perforation:

Barium/endoscopy contraindicated — confirmed by erect CXR (free air under diaphragm)
Urgent surgical consultation — laparoscopic or open repair
Mortality 30–50% in elderly/debilitated patients

Gastric outlet obstruction:

Endoscopic balloon dilatation or surgical intervention

Summary Algorithm

Dyspepsia
    ├── Alarm symptoms or age >45?
    │       └── YES → Urgent Upper GI Endoscopy + Biopsy
    │
    └── NO (young, uncomplicated)
            └── Test for H. pylori (stool antigen)
                    ├── POSITIVE → 14-day Triple Therapy + PPI
                    │              → Confirm eradication (UBT at 4 weeks)
                    └── NEGATIVE → Empirical PPI trial (4–8 weeks)
                                   → Endoscopy if symptoms persist

Key Sources: Yamada's Textbook of Gastroenterology (7th ed.) | Textbook of Family Medicine 9e | Sleisenger and Fordtran's GI and Liver Disease | Lippincott Illustrated Reviews: Pharmacology

Weight loss

Asking for Preferences

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Here is a comprehensive clinical overview of Unintentional (Involuntary) Weight Loss sourced from Harrison's Principles of Internal Medicine, Goldman-Cecil Medicine, and Yamada's Textbook of Gastroenterology.

Unintentional Weight Loss

Definition

Clinically significant unintentional weight loss (UWL) = loss of >5% of usual body weight over 6–12 months.

Threshold	Clinical Significance
>5% in 6–12 months	Clinically important; warrants investigation
>10% of body weight	Associated with protein-energy malnutrition and impaired physiological function
>20% of body weight	Nutritional deficiencies and multi-organ dysfunction

"In a representative US sample, 5% of adults aged 45–54 reported involuntary weight loss of ≥5% of body weight. Prevalence rises to 15–20% in those over 65 years." — Yamada's Textbook of Gastroenterology

UWL is associated with a 22–39% excess mortality rate, primarily reflecting the severity of the underlying pathology.

Pathophysiology

Three fundamental mechanisms drive weight loss:

Reduced appetite/food intake — anorexia, pain, psychiatric illness, medications
Impaired nutrient absorption — malabsorption syndromes, pancreatic insufficiency
Increased catabolism — cytokine-driven (cancer, chronic infections, inflammatory disease)

The Cachexia Pathway (Cancer & Chronic Disease)

Proinflammatory cytokines — IL-1, IL-2, IL-6, interferon-γ, TNF-α — are the key mediators:

Activate NF-κB → ↓ muscle protein synthesis
Activate ubiquitin-mediated proteolysis → muscle breakdown
Stimulate lipolysis → loss of adipose tissue
Suppress appetite via hypothalamic pathways

"Cytokines also activate the ubiquitin-mediated proteolytic system, which is the principal mechanism for protein catabolism in disease-related catabolic states, including cancer." — Yamada's Textbook of Gastroenterology

Cancer cachexia is distinct from non-cancer weight loss: it involves loss of both adipose tissue AND skeletal muscle, whereas simple starvation primarily depletes fat. It affects up to 80% of GI and pancreatic cancer patients.

Causes of Unintentional Weight Loss

1. Malignancy (~16–40% of cases)

The single most important cause to exclude. ~50% of weight loss-associated malignancies are gastrointestinal.

Cancer Type	Notes
Gastric cancer	Often asymptomatic early; no localising symptoms
Pancreatic cancer	Classical cause; may present with weight loss before pain
Colon cancer	Change in bowel habit, occult blood
Hepatocellular carcinoma	Especially in cirrhotic patients
Lung cancer	Particularly in smokers
Haematological	Lymphoma, leukaemia — fever, night sweats
Breast, ovarian, genitourinary, prostate

"Malignancy that reveals itself through significant weight loss usually has a very poor prognosis." — Harrison's 22E "Up to 20% of all cancer deaths are caused directly by cachexia."

2. Gastrointestinal Disorders

Peptic ulcer disease
Inflammatory bowel disease (especially Crohn's disease)
Malabsorption (coeliac disease, pancreatic insufficiency, bacterial overgrowth)
Dysmotility / gastroparesis
Chronic pancreatitis
Atrophic gastritis
Cirrhosis
Chronic intestinal ischaemia (postprandial pain, "food fear")
Oral/dental problems (caries, abscess, poor dentition, xerostomia)

3. Metabolic & Endocrine Disorders

Condition	Mechanism
Hyperthyroidism	↑ metabolic rate; weight loss despite increased appetite
Diabetes mellitus (uncontrolled)	Glycosuria, osmotic diuresis, relative insulin deficiency
Addison's disease	Cortisol deficiency, anorexia, nausea
Phaeochromocytoma	Catecholamine excess, ↑ catabolism

4. Chronic Infections

Infection	Notes
Tuberculosis	Classic constitutional weight loss, night sweats, cough
HIV	~25% of undiagnosed HIV presents with weight loss; 40% co-infection with TB in some regions
Subacute bacterial endocarditis	Fever, embolic phenomena
Chronic abscesses / parasitic infections

5. Psychiatric Disorders

Condition	Features
Depression	Anorexia, loss of interest in food; commonest psychiatric cause
Anorexia nervosa	Especially young women; body image distortion
Dementia	Forgetting to eat; cognitive decline
Anxiety disorders
Alcohol/substance use	Nutritional neglect

6. Medications (Drug-induced Anorexia/Weight Loss)

Drug	Mechanism
SSRIs	Serotonergic anorexia
Metformin	GI intolerance, nausea
NSAIDs	GI mucosal damage, nausea
Levodopa	Nausea, dysgeusia
ACE inhibitors	Dysgeusia
Sedatives	Reduced interest in food
Chemotherapy	Nausea, mucositis
Digoxin, antibiotics	GI side effects

7. Chronic Organ Disease

Chronic kidney disease — uraemic anorexia, dysgeusia
Chronic heart failure — cardiac cachexia; cytokine-mediated
COPD — increased work of breathing, systemic inflammation
Rheumatoid arthritis / vasculitis (e.g. polyarteritis nodosa)

8. Physiological / Social Causes (Especially Elderly)

Anorexia of ageing (↓ smell/taste, slowed gastric emptying, early satiety)
Social isolation, poverty, immobility
Visual impairment
Functional decline, frailty

Investigations

First-line (All Patients)

Test	Rationale
Full blood count (FBC)	Anaemia (chronic disease, GI blood loss, B12/folate deficiency)
ESR / CRP	Inflammation, infection, malignancy
Urea, electrolytes, creatinine	Renal disease, dehydration
Liver function tests	Hepatic malignancy, cirrhosis
Thyroid-stimulating hormone (TSH)	Hyperthyroidism
Fasting glucose	Diabetes
Urinalysis	Glycosuria, proteinuria
Chest X-ray	Lung cancer (mandatory in smokers >40 years, or with respiratory symptoms)
Faecal occult blood test (FOBT)	GI malignancy screen
HIV serology	Low threshold if unexplained; especially with TB risk factors

"The cause of weight loss is usually evident from the history, physical examination, and routine laboratory studies." — Goldman-Cecil Medicine

Second-line (Directed by First-line Results)

Finding	Next Step
↑ appetite + weight loss	TSH, fasting glucose, malabsorption screen
GI symptoms	Upper GI endoscopy + biopsy, colonoscopy, CT abdomen
Malabsorption suspected	Faecal fat (elastase), anti-tissue transglutaminase (coeliac), small bowel biopsy
Lymphadenopathy / haematological abnormality	CT chest/abdomen/pelvis, bone marrow biopsy
Respiratory symptoms / smoking	CT chest, bronchoscopy
Suspicion of infection	TB (Interferon-γ release test / IGRA), HIV, blood cultures
Psychiatric features	Formal psychiatric evaluation
Tumour markers (when relevant)	CEA, CA 19-9 (pancreatic/GI), AFP (liver), PSA (prostate)

Advanced Imaging

Modality	Role
CT abdomen/pelvis	First-line cross-sectional imaging; detects most intra-abdominal causes
PET/CT (FDG)	Highest sensitivity for occult neoplasia, infection, vasculitis; appropriate when simpler tests are negative
MR angiography	Mesenteric ischaemia, vasculitis (e.g. polyarteritis nodosa)
Isotope bone scan	Bony metastases (being superseded by PET/CT)
Mammography	Women >50 years with unexplained weight loss

"PET/CT probably has the greatest sensitivity for detection of disorders likely to be relevant to weight loss (neoplasia, infection, vasculitis)." — Yamada's Textbook of Gastroenterology

Management Principles

The cornerstone is treating the underlying cause. In addition:

Strategy	Detail
Treat underlying disease	Cancer, infection, endocrine disorder, depression
Stop/switch offending medications	Review all drugs for anorectic side effects
Oral nutritional supplements	High-energy drinks between (not with) meals to minimise appetite suppression
Nutritional support	Enteral/parenteral nutrition in severe malnutrition
Mirtazapine	Antidepressant that significantly increases body weight, body fat mass, and leptin; use in selected patients (side effects: dizziness, fatigue, somnolence ~10%)
Exercise programme	Gains muscle protein mass, strength and endurance in wasting conditions
Social support	Address poverty, isolation, mobility limitations in elderly

"Orexigenic, anabolic, and anticytokine agents are not generally recommended [for unexplained UWL]." — Harrison's Principles of Internal Medicine, 22E

Key Red Flag "Alarm" Features Requiring Urgent Investigation

Age >45 years with new-onset weight loss
Smoking history (especially men)
Dysphagia or odynophagia
Haematemesis or melaena
Persistent vomiting
Palpable abdominal mass or lymphadenopathy
Abnormal blood tests (anaemia, elevated LFTs, elevated inflammatory markers)
Weight loss >10% body weight

Important note: In up to 25% of patients, no cause of weight loss is found even after thorough investigation. These patients still carry an increased risk of cancer diagnosis within 2 years and warrant follow-up.

Sources: Harrison's Principles of Internal Medicine 22E | Goldman-Cecil Medicine (International Edition) | Yamada's Textbook of Gastroenterology (7th ed.)

This is a shared conversation. Sign in to Orris to start your own chat.